ENTITY
Venus Medtech (Hangzhou)

Venus Medtech (Hangzhou) (2500 HK)

111
Analysis
Health Care • China
Venus Medtech is a leading medical device company specializing in transcatheter structural heart valvular therapies. It develops and commercializes innovative solutions for all four heart valves (TAVR, TPVR, TMVR, TTVR) and interventional hypertension treatment. The company was founded in 2009 and is headquartered in Hangzhou, China.
more
bullish•Kangji Medical
•16 Aug 2020 17:17

HSCI Index Rebalance - Stock Connect Flows Coming Up

The Hang Seng Indexes Company Limited (HSIL) announced the results of its review of the Hang Seng Family of Indexes post market close on 14 August....

Logo
722 Views
Share
•22 Jul 2020 05:39

HSCI and Stock Connect - Biotech Stocks Now Eligible; Inclusion & Exclusion Possibilities

Hang Seng Indexes Company (HSIL) reviews the constituents of the Hang Seng Composite Index (HSCI) on a half yearly basis in March and September...

Logo
1.1k Views
Share
bullish•Kangji Medical
•28 Jun 2020 13:45

Kangji Medical IPO: Trading Debut

Kangji Medical (9997 HK) is the largest domestic minimally invasive surgical instruments and accessories (MISIA) platform in China, with a 2.7%...

Logo
615 Views
Share
•16 Jun 2020 19:19

Hygeia Healthcare IPO (Part I): A Better Healthcare

Hygeia Healthcare is an oncology healthcare service provider in China who operates hospitals as well as provides third-party radiotherapy services...

Share
bullish•Kangji Medical
•16 Jun 2020 00:25

Kangji Medical IPO: Valuation Insights

Kangji Medical (1498779D CH) is the largest domestic minimally invasive surgical instruments and accessories (MISIA) platform in China, with a 2.7%...

Logo
520 Views
Share
x